Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - ROCKET PHARMACEUTICALS, INC. | itek-ex312_6.htm |
| EX-31.1 - EX-31.1 - ROCKET PHARMACEUTICALS, INC. | itek-ex311_9.htm |
| 10-Q - 10-Q - ROCKET PHARMACEUTICALS, INC. | itek-10q_20170331.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report on Form 10-Q of Inotek Pharmaceuticals Corporation (the “Company”) for the period ended March 31, 2017, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to his knowledge:
|
1) |
the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
2) |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: May 10, 2017 |
|
|
/s/ David P. Southwell |
|
|
|
|
David P. Southwell |
|
|
|
|
President, Chief Executive Officer and Director (Principal Executive Officer) |
|
|
|
|
|
|
Date: May 10, 2017 |
|
|
/s/ Dale Ritter |
|
|
|
|
Dale Ritter |
|
|
|
|
Vice President–Finance (Principal Financial Officer) |